Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) saw strong trading volume on Tuesday. Approximately 2,556,335 shares changed hands during trading, an increase of 493% from the average daily volume of 430,965 shares. The stock last traded at $7.30 and had previously closed at $7.54.
Wall Street Analyst Weigh In
Separately, Barclays upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Coloplast A/S has a consensus rating of “Moderate Buy”.
Read Our Latest Report on CLPBY
Coloplast A/S Stock Performance
The company has a debt-to-equity ratio of 1.51, a quick ratio of 0.94 and a current ratio of 1.56. The stock has a market cap of $16.43 billion, a PE ratio of 34.71, a PEG ratio of 2.85 and a beta of 0.10. The company’s 50-day moving average price is $6.86 and its two-hundred day moving average price is $6.78.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.09 EPS for the quarter, meeting analysts’ consensus estimates of $0.09. Coloplast A/S had a return on equity of 42.25% and a net margin of 10.57%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.12 billion. On average, equities research analysts forecast that Coloplast A/S Sponsored ADR will post 0.40 EPS for the current year.
About Coloplast A/S
Coloplast A/S is a Danish medical device company that develops and markets products and services for people with intimate health care needs. Its main business areas include ostomy care, continence care, wound and skin care, and urology care. Its products include ostomy bags and accessories, catheters and other continence products, wound dressings, and devices used in urological procedures. Coloplast also provides voice and respiratory care products, including solutions for people who have had a laryngectomy.
Further Reading
- Five stocks we like better than Coloplast A/S
- Microsoft’s Neocloud Pullback Isn’t a Crack in AI Demand
- Fox’s $22 Billion Roku Acquisition Reshapes Its Streaming Business
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
